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HIV/AIDS epidemiology, pathogenesis, prevention, and 
treatment
Viviana Simon, David D Ho, Quarraisha Abdool Karim
The HIV-1 pandemic is a complex mix of diverse epidemics within and between countries and regions of the world, 
and is undoubtedly the defi ning public-health crisis of our time. Research has deepened our understanding of how 
the virus replicates, manipulates, and hides in an infected person. Although our understanding of pathogenesis and 
transmission dynamics has become more nuanced and prevention options have expanded, a cure or protective vaccine 
remains elusive. Antiretroviral treatment has transformed AIDS from an inevitably fatal condition to a chronic, 
manageable disease in some settings. This transformation has yet to be realised in those parts of the world that 
continue to bear a disproportionate burden of new HIV-1 infections and are most aff ected by increasing morbidity 
and mortality. This Seminar provides an update on epidemiology, pathogenesis, treatment, and prevention 
interventions pertinent to HIV-1.
HIV pandemic
An estimated 38·6 (33·4–46·0) million people live with 
HIV-1 worldwide, while about 25 million have died 
already.1 In 2005 alone, there were 4·1 million new 
HIV-1 infections and 2·8 million AIDS deaths.1 These 
estimates mask the dynamic nature of this evolving 
epidemic in relation to temporal changes, geographic 
distribution, magnitude, viral diversity, and mode of 
transmission. Today, there is no region of the world 
untouched by this pandemic (fi gure 1).2
Heterosexual transmission remains the dominant 
mode of transmission and accounts for about 85% of all 
HIV-1 infections. Southern Africa remains the epicentre 
of the pandemic and continues to have high rates of 
new HIV-1 infections.3 Although overall HIV-1 
prevalence remains low in the emerging epidemics in 
China and India, the absolute numbers, which are fast 
approaching those seen in southern Africa, are of 
concern.1 Outside of sub-Saharan Africa, a third of all 
HIV-1 infections are acquired through injecting drug 
use, most (an estimated 8·8 million) of which are in 
eastern Europe and central and southeast Asia.1 The 
rapid spread of HIV-1 in these regions through injecting 
drug use is of importance, since it is a bridge for rapid 
establishment of more generalised epidemics.
A defi ning feature of the pandemic in the current 
decade is the increasing burden of HIV-1 infections in 
women,4 which has additional implications for 
mother-to-child transmission. Women now make up 
about 42% of those infected worldwide; over 70% of 
whom live in sub-Saharan Africa.1 Overall, a quarter of 
all new HIV-1 infections are in adults aged younger 
than 25 years.1 HIV-1 infection rates are three to six 
times higher in female adolescents than in their male 
counterparts,1,5–7 and this diff erence is attributed to 
sexual coupling patterns of young women with older 
men. Population prevalence of HIV-1 infection, 
concurrent sexual relationships, partner change, sexual 
practices, the presence of other sexually transmitted 
diseases,8–11 and population mobility patterns12–14 for 
economic and other reasons (eg, natural disasters and 
wars) further increase the probability of HIV-1 
acquisition.3,15 Emerging data accord with strong links 
between risk of sexual HIV-1 acquisition and episodic 
recreational drug or alcohol use.16 
Although sub-Saharan Africa continues to bear a 
disproportionate burden of HIV-1 infections, there is 
now an increasing number of countries reporting 
stabilisation or declines in prevalence (eg, Zambia, 
Tanzania, Kenya, Ghana, Rwanda, Burkina Faso, and 
Zimbabwe).1 There is some evidence to attribute these 
reductions to eff ective changes in sexual behaviour, 
such as postponement of sexual debut, reduction in 
casual relationships, and more consistent condom use 
in casual relationships.17,18 However, increasing 
morbidity and mortality rates associated with a maturing 
HIV-1 epidemic need to be considered when interpreting 
these data.19 For example, the death of a few high-risk 
individuals who are key to transmission chains could 
exert a major eff ect on sexual networks and result in 
major reductions in infection rates.20 Additionally, since 
most HIV-1 estimates are based on surveys in antenatal 
populations, increasing morbidity and mortality could 
cause the numbers of women in this group to decrease, 
and thus lead to underestimates of the true prevalence 
in these countries.19
Although the relative contribution of cell-free virus 
compared with cell-associated virus in HIV-1 
transmission remains unclear, there is growing 
evidence that viral load is predictive of transmission 
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Search strategy and selection criteria
A comprehensive literature review was undertaken by searching the PubMed database 
online, for English language publications between January, 2000, and June, 2006. The 
database search terms included keywords such as “HIV/AIDS”, “epidemiology”, 
“prevention”, “pathogenesis”, “HSV-2”, “male circumcision”, “PMTCT”, “scaling up 
treatment”, “resource constrained settings”, “antiretroviral pre-exposure prophylaxis”, 
“HAART”, “restriction”, “host factor”, “HIV pathogenesis”, “resistance”, “latency”. Various 
combinations of these words were entered. All duplicate articles were removed. A subset 
of relevant articles was chosen and full-text manuscripts were summarised. 
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risk.21,22 The highest levels of viraemia are seen during 
acute infection and advanced HIV-1 disease.22 Further, 
co-infections with other sexually transmitted diseases 
in asymptomatic HIV-1 infected people can increase 
viral shedding to levels similar to those seen during 
acute infection.23 Thus, sexually transmitted diseases 
could enhance HIV-1 transmission to rates similar to 
those seen during primary infection.24 This observation 
could help to explain why the effi  ciency of HIV-1 
transmission exceeds, in some settings, the earlier 
mathematical projections.25 Thus, identifi cation and 
treatment of recently infected people is an important 
means to reduce transmission. However, most people 
are unaware of their HIV-1 status during these crucial 
fi rst months of infection. Several screening strategies 
based on laboratory testing and clinical algorithms are 
being developed and tested26 for effi  cient identifi cation 
of early infection before antibody development.27 
Additionally, a more aggressive management of sexually 
transmitted infections in settings with generalised 
epidemics has the potential to aff ect current epidemic 
trajectories.24 
Based on their genetic make-up, HIV-1 viruses are 
divided into three groups (eg, M [main], N, and O group, 
fi gure 2). These HIV-1 groups and HIV-2 probably result 
from distinct cross-species transmission events.28 
Pandemic HIV-1 has diversifi ed into at least nine subtypes 
(fi gures 1 and 2) and many circulating recombinant 
forms,29,30 which encode genetic structures from two or 
more subtypes (eg, A/E=CRF01; A/G=CRF02). The 
continuously evolving HIV-1 viral diversity poses an 
immense challenge to the development of any preventive 
or therapeutic intervention.29 
In terms of viral diversity, subtype C viruses continue 
to dominate and account for 55–60% of all HIV-1 
infections worldwide (fi gure 1).30 Non-subtype B isolates 
might diff er in their virological characteristics from the 
subtype B isolates (eg, viral load, chemokine co-receptor 
usage, transcriptional activation in specifi c biological 
compartments).31–33 However, the clinical consequences 
of subtype variations remain unclear. 
Infection with two or more genetically distinct viruses 
could lead to new recombinant viruses. Recombination 
takes place at a higher rate than initially predicted,30 and 
circulating recombinant forms account for as much as 
20% of infections in some regions (eg, southeast Asia).31 
These fi ndings are in agreement with the occurrence of 
co-infections with multiple distinct isolates in a close 
temporal context.34–36 Further, superinfections in which 
time points of virus acquisition are months to years 
apart have been described, although at a much lower 
frequency than co-infections.34,37–39 Collectively, these 
observations challenge the assumption that HIV-1 
acquisition happens only once with a singular viral 
strain and that, thereafter, the infected individual is 
protected from subsequent infections.40 This lack of 
immunisation has substantial implications for vaccine 
development. Emerging evidence suggests that clinical 
progression to AIDS might be more rapid in individuals 













































Figure 1: Worldwide distribution of HIV-1 infections, modes of transmission, and HIV-1 subtypes 
HSex=heterosexual. MSM=Men who have sex with men. IDU=injection drug users. Based on Joint UNAIDS and WHO AIDS epidemic update December, 2005. 
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practices in viraemic HIV-1-infected people might be 
appropriate to keep recurrent exposure to new viral 
strains to a minimum. 
Pathogenesis of HIV-1 
The worldwide spread of HIV-1 indicates that the virus 
eff ectively counteracts innate, adapted, and intrinsic 
immunity.41,42 Despite its modest genome size (less than 
10 kb) and its few genes (fi gure 3), HIV-1 excels in taking 
advantage of cellular pathways while neutralising and 
hiding from the diff erent components of the immune 
system.43–45 Notably, our understanding of pathogenesis is 
often derived from studies of subtype B viruses and 
non-human primate studies. 
The HIV-1 life cycle is complex (fi gure 3) and its 
duration and outcome is dependent on target cell type 
and cell activation.46 In the early steps, HIV-1 gains access 
to cells without causing immediate lethal damages but 
the entry process can stimulate intracellular signal 
cascades, which in turn might facilitate viral replication.47,48 
The two molecules on the HIV-1 envelope, the external 
glycoprotein (gp120) and the transmembrane protein 
(gp41), form the spikes on the virion’s surface.49 During 
the entry process, gp120 attaches to the cell membrane 
by fi rst binding to the CD4+ receptor. Subsequent 
interactions between virus and chemokine co-receptors 
(eg, CCR5, CXCR4) trigger irreversible conformational 
changes.49,50 The actual fusion event takes place within 
minutes by pore formation,50,51 and releases the viral core 
into the cell cytoplasm. After the core disassembles, the 
viral genome is reverse transcribed into DNA by the 
virus’ own reverse transcriptase enzyme.46 Related yet 
distinct viral variants can be generated during this 
process since reverse transcriptase is error prone and has 
no proofreading activity.46 At the midpoint of infection, 
the viral protein integrase in conjunction with host DNA 
repair enzymes inserts the viral genome into gene-rich, 
transcriptionally active domains of the host’s 
chromosomal DNA.52–54 An integrase binding host factor, 
LEDGF/p75 (lens epithelium-derived growth factor), 
facilitates integration,55,56 which marks the turning point 
by irreversibly transforming the cell into a potential virus 
producer. In the late steps, production of viral particles 
needs host driven as well as virus driven transcription.46 
Viral proteins are transported to and assemble in 
proximity to the cell membrane. Virus egress from the 
cell is not lytic and takes advantage of the vesicular 
sorting pathway (ESCRT-I, II, III), which normally 
mediates the budding of endosomes into multivesicular 
bodies.57,58 HIV-1 accesses this protein-sorting pathway by 
binding TSG101 via its late domain, a short sequence 
motif in p6 of Gag.59,60 Cleavage of the Gag-Pol poly-
protein by the viral protease produces mature infectious 
virions.46,61
Since cytoplasmic molecules of the producer cell and 
components from its cell surface lipid bilayer are 
incorporated into the new viral particle, virions bear 
characteristics of the cells in which they were produced.62 
Incorporated host molecules can determine the virus’ 
phenotype in diverse ways (eg, shape the replicative 
features in the next cycle of infection or mediate immune 
activation of bystander cells62). 
Studies of the early events that happen after HIV-1 
breaches the mucosal barrier suggest the existence of a 
window period in which viral propagation is not yet 
established and host defences could potentially control 
viral expansion.63 The important co-receptors for HIV-1 
infection are two chemokine receptors—CCR5 and 
CXCR4. Independently of the transmission route, most 
new infections are established by viral variants that rely 
on CCR5 usage.64 CXCR4-tropic viruses generally appear 
in late stages of infection and have been associated with 
increased pathogenicity and disease progression.65 
Compelling evidence from non-human primate models 
(eg, simian immunodefi ciency virus [SIV] infection of 
rhesus macaques) suggest that vaginal transmission 
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Figure 2: Phylogenetic relation of lentiviruses in man and non-human 
primates 
The HIV-1 pandemic is largely due to viral isolates belonging to the HIV-1 
M-group, with HIV-1 subtype C being the most prevalent (red). Recombinant 
circulating forms cluster with the M-group but have been omitted for clarity. 
HIV-1 M group and the contemporary SIV strains identifi ed in wild chimpanzees 
in Cameroon (SIVcpzLB7/EK528) are highlighted. HIV-1 sequences cluster closely 
with SIV from chimpanzees (SIVcpz), whereas HIV-2 resembles SIV from 
macaques and sooty mangabeys (SIVmac/SIVsm).
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T lymphocytes, macrophages, and dendritic cells located 
in the lamina propria.63 Potential pathways for virus 
transmission involve endocytosis, transcytosis, and virus 
attachment to mannose C-type lectin receptors (eg, 
DC-SIGN) located on dendritic cells and macrophages.66 
The initial replication takes place in the regional lymph 
organs (eg, draining lymph nodes) and is composed of 
few viral variants, and leads to modest primary 
amplifi cation. With migration of infected T lymphocytes 
or virions into the bloodstream, secondary amplifi cation 
in the gastrointestinal tract, spleen, and bone marrow 
results in massive infection of susceptible cells. In close 
temporal relation with the resulting peak of viraemia (eg, 
106 to 107 copies per mL plasma), clinical symptoms can 
be manifest during primary HIV-1 infection (fi gure 4). 
The level of viraemia characteristic for the chronic phase 
of infection in an individual (viral set point) diff ers from 
the peak viraemia by one or two orders of magnitude. 
This reduction is largely attributed to HIV-1 specifi c 
CD8+ responses but target cell limitation could also play 
a part. The viral population is most homogeneous early 
after transmission, but as viral quasi-species diversify in 
distinct biological compartments, mutant viruses that 
are resistant to antibody neutralisation, cytotoxic T cells, 
or antiretroviral drugs are generated and archived in 
long-lived cells (ie, viral reservoirs). 
A pronounced depletion of activated as well as memory 
CD4+ T cells located in the gut-associated lymphoid 
tissues has been seen in individuals identifi ed early after 





















































Figure 3: HIV-1 is a retrovirus that encodes three structural genes (Gag, Pol, and Env) 
(A) Envelope glycoproteins gp120/41 form the spikes on the virion’s surface. During maturation the gag protein is cleaved and Gag p24 forms the core. The viral 
genome, viral reverse transcriptase (RT), integrase as well as a number of host proteins are encapsidated. (B) Diff erent steps of the viral life cycle on a cellular level and 
the potential targets for treatment interventions. (C) HIV-1 has evolved strategies to counteract the restriction factors TRIM5α and APOBEC3G/3F. If left unchecked 
by HIV-1 Vif, APOBEC3G/3F is encapsidated into the egressing virion, and on infection of a target cell leads to G-to-A hypermutations in the viral genome. Rhesus 
TRIM5α inhibits HIV-1 replication early after infection of the target cell before the step of reverse transcription.
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in the mucosal lymphoid tissues remains despite years of 
antiretroviral treatment, a striking observation that 
contrasts with the fact that the number of CD4+ 
T lymphocytes in the peripheral blood can return to 
normal under antiretroviral treatment. 
A gradual destruction of the naive and memory CD4+ 
T-lymphocyte populations is the hallmark of HIV-1 
infection, with AIDS being the last disease stage 
(fi gure 4).68 Despite the frequent absence of symptoms 
during early and chronic phase, HIV-1 replication is 
dynamic throughout the disease. The half-life of a single 
virion is so short that half the entire plasma virus 
population is replaced in less than 30 minutes,69 and the 
total number of virions produced in a chronically infected 
person can reach more than 10¹⁰ particles per day.69,70 The 
turnover rates of lymphocyte populations are upregulated 
many fold during HIV-1 infection, whereas cell 
proliferation decreases once viral replication is reduced 
by antiretroviral treatment.71,72 Diff erent depletion 
mechanisms have been proposed, with an emerging 
consensus favouring generalised immune activation as 
cause for constant depletion of the CD4+ cell reservoir.73 
Immune activation predicts disease progression74 and, 
thus, seems to be a central feature of pathogenic HIV-1 
infections. Recently, Nef proteins from SIV lineages that 
are non-pathogenic in their natural hosts (eg, African 
green monkeys) have proved to down-regulate CD3-T-cell 
receptors, resulting in reduced cell activation and 
apoptosis.75 HIV-1 Nef fails to quench T-cell activation, 
possibly leading to the high degree of immune activation 
seen in infected people.
Understanding the mechanisms that lead to protection 
or long-lasting control of infection will guide vaccine 
development by providing correlates of protection. Natural 
resistance to HIV-1 infection is rare and varies greatly 
between individuals. Two groups—long-term non-pro-
gressors and highly exposed persistently seronegative 
individuals—have been studied widely to identify innate 
and acquired protective determinants (table 1).76 Host 
resistance factors consist of human leucocyte antigen 
(HLA) haplotypes, autoantibodies, mutations in the 
promoter regions, and coding regions of the co-receptors 
CCR5 and CCR2, as well as the up-regulation of chemokine 
production (table 1).76,77 Indeed, individuals encoding a 
truncated CCR5 version (CCR5Δ32) have slower disease 
progression (heterozygote) or are resistant to CCR5-using 
viruses (homozygote).78 The CCL3L1 gene encodes MIP1α, 
a CCR5 co-receptor ligand and chemokine with antiviral 
activity. Recent fi ndings show that CCL3L1 gene copies 
vary individually and higher numbers of gene duplications 
result in reduced susceptibility to infection,77,79 possibly 
by competitive saturation of CCR5 co-receptor. Cyto-
toxic T-lymphocyte responses, helper T-cell functions, and 
humoral responses are some of the acquired factors that 
modulate the risk of transmission in highly exposed 
persistently seronegative individuals,76 and could also 
contribute to spontaneous control of replication in long-
term non-progressors. The putative protective role of 
cytotoxic T-lymphocyte activity has been suggested in 
seronegative sex workers and in some long-term non-
progressors.76,80
Mammalian cells are not welcoming micro-environ-
ments, but rather deploy a defensive web to curb 
endogenous and exogenous viruses. HIV-1’s ability to 
circumvent these defences is as impressive as its effi  ciency 
to exploit the cellular machinery. APOBEC3G/3F and 
TRIM5α are recently described intrinsic restriction factors 
that are constitutively expressed in many cells.81,82 Both 
gene loci have been under strong selective pressure 
Innate Genetic Acquired Intrinsic
Autoantibodies HLA haplotype Cytotoxic T-cell activity APOBEC3G/3F
Chemokines CCR5 gene/promoter Helper T-cell function TRIM5α
Cytokines CCR2 gene/promoter Neutralising antibodies
CCL3L1 gene copy number
HLA=human leucocyte antigen. CCR5=chemokine receptor 5. CCR2=chemokine receptor 2. CCL3L1=CC chemokine 
ligand like-1, APOBEC3G/3F=apolipoprotein B mRNA editing complex 3.
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Figure 4: The course of HIV-1 infection defi ned by the level of viral replication 
Plasma viraemia (top), and dynamic changes of the CD4+ T-lymphocyte compartments (bottom). Primary 
infection characterised by high plasma viraemia (red line, top), low CD4 cells (green line, bottom), and absence of 
HIV-1 specifi c antibodies (orange line, bottom). Viraemia drops as cytotoxic CD8+ T-lymphocytes (CTL) develop 
(blue line, bottom) and an individual viral-load set point is reached during chronic infection. Viral set points diff er 
greatly among individuals (eg, red dotted line, top) and predict disease progression. Viral diversity increases 
through out the disease (closed circles, top). The risk of transmission is highest in the fi rst weeks when viraemia 
peaks (closed circles, top). GALT=gut-associated lymphoid tissues. 
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throughout primate evolution,83 indicating an ancient need 
to neutralise foreign DNA and maintain genome stability 
that precedes the current HIV-1 pandemic.
APOBEC3 enzymes (A3) belong to the superfamily of 
cytidine deaminases,84 a group of intracellular proteins 
with DNA/RNA editing activity.84,85 Most representatives 
of the APOBEC3 group have some mutagenic potential 
and restrict endogenous retroviruses and mobile genetic 
elements. The deaminases A3G, A3F, and A3B have 
potent antiviral activity, with the fi rst two being expressed 
in cells that are susceptible to HIV-1 infection 
(T-lymphocytes, macrophages). HIV-1 evades APOBEC3 
mutagenesis by expressing Vif, which leads to 
APOBEC3G/3F but not A3B degradation.42,86–90 
We still need to establish how the mechanisms of DNA 
editing and antiviral activity are interwoven, since some 
antiviral activity can be maintained despite defective 
DNA editing.91 The early replication block in non-
stimulated CD4+ T cells has been attributed to low 
molecular mass complexes of APOBEC3G.92 
Hypermutated genomes in HIV-1 infected patients93 and 
mutations in Vif resulting in abrogated or diff erential 
APOBEC3 neutralisation capacity have been described.94,95 
The degree to which APOBEC3G/3F mRNA expression 
predicts clinical progression remains an area of intensive 
investigation.96,97
Several representatives of the heterogeneous family of 
tripartite motif proteins (TRIM) inhibit retroviruses in a 
species-specifi c manner.81,98 TRIM5α from rhesus 
macaques and African green monkeys inhibit HIV-1 
replication, whereas the human homologue is inactive 
against SIV and HIV-1, leading to the recorded 
susceptibility of human cells to both viruses.81 Rhesus 
TRIM5α recognises the capsid domain of HIV-1 Gag and 
manipulates the kinetics of HIV-1 core disassembly 
within minutes after cell entry.99,100 Thus, experimental 
approaches to render HIV-1 resistant to rhesus TRIM5α 
could lead to immunodefi ciency viruses capable of 
replicating in rhesus macaques. Such a non-primate 
model would allow testing of antiviral treatment and 
vaccine interventions with HIV-1 viruses instead of SIV 
or SIV/HIV chimeric viruses. 
Clinical management 
Diagnosis
The diagnosis of HIV-1 infection is based on the detection 
of specifi c antibodies, antigens, or both, and many 
commercial kits are available. Serological tests are 
generally used for screening. A major advance has been 
the availability of rapid HIV-1 antibody tests. These assays 
are easy to do and provide results in as little as 
20 minutes,101 enabling specimen collection and proper 
diagnosis at the same visit. Rapid tests are important 
tools for surveillance, screening, and diagnosis, and can 
be reliably done on plasma, serum, whole blood, or saliva 
by health-care providers with little laboratory expertise. 
The two limitations of these serological tests are detection 
of infection during primary infection when antibodies 
are absent, and in infants younger than 18 months who 
might bear maternal HIV-1 antibodies. In these instances 
direct virus detection is the only option (eg, quantifi cation 
of viral RNA [standard] or p24 antigen in heat denatured 
serum [less expensive]). 
For staging purposes, measurement of CD4+ cells and 
viraemia is required. Plasma viral load is widely used to 
monitor therapeutic success on antiretroviral treatment. 
Several commercially available tests provide sensitive 
quantifi cation of plasma HIV-1 RNA copies. The newer 
versions of the Amplicor and Quantiplex (Roche, 
Indianapolis, IN, USA, and Bayer Diagnostics, Walpole, 
MA, USA, respectively) assays have overcome initial 
suboptimum performance for non-B subtypes.102 While 
Entry Reverse transcriptase Protease
Nucleoside Nucleotide Non-nucleoside













Drugs belong to fi ve drug classes and target three diff erent viral steps (entry, reverse transcription, or protease). Availability of these drugs in resource-limited countries is 
subject to country specifi c licensing agreements. 
Table 2: Antiretroviral drugs currently approved by US Food and Drug Administration
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the viral load determines the rate of destruction of the 
immune system, the number of CD4+ cells reveals the 
degree of immunodefi ciency and is, therefore, used to 
assess the stage of infection. CD4+ cell counts together 
with clinical manifestations (eg, occurrence of 
opportunistic infections) are key criteria for HIV-1 disease 
classifi cation. Flow cytometry analysis is the standard 
method for CD4+ cells quantifi cation. 
Standard methods for quantifying viral load and CD4+ 
cell counts need advanced laboratory infrastructures, and 
assays require a specimen to be tested within a short 
time of collection. These requirements pose challenges 
for resource-constrained settings. The use of dried blood 
spot specimen has resolved some of the diffi  culties 
associated with transportation of samples needed for 
virological assessments.103 Measurement of reverse 
transcriptase activity in plasma samples, simplifi cation 
of gene amplifi cation methods (eg, Taqman technology), 
and paper-strip quantifi cation (dipstick assays) might 
provide cost-eff ective alternatives for the future.104–106 
Similarly microcapilliary fl ow-based systems, CD4+ 
chips, or total white counts (panleucocyte gating) provide 
alternatives for establishment of the level of 
immunodefi ciency in resource-limited settings.107–110 
Drug treatment
Antiretroviral compounds 
Antiretroviral treatment is the best option for longlasting 
viral suppression and, subsequently, for reduction of 
morbidity and mortality. However, current drugs do not 
eradicate HIV-1 infection and lifelong treatment might 
be needed.
20 of the 21 antiretroviral drugs currently approved by 
the US Food and Drug Administration target the viral 
reverse transcriptase or protease (table 2). Eight 
nucleoside/nucleotide analogues and three non-nucleo-
side reverse transcriptase inhibitors inhibit viral 
replication after cell entry but before integration. Fixed-
dose combination tablets simplify treatment regimens by 
reducing the daily pill burden, and drugs with long half-
lives allow once or twice daily dosing. Eight protease 
inhibitors prevent the maturation of virions resulting in 
production of non-infectious particles. The recently 
approved darunavir (June, 2006) is the fi rst of its class that 
retains activity against viruses with reduced susceptibility 
to protease inhibitors. Enfuvirtide targets a gp41 region of 
the viral envelope and stops the fusion process before the 
cell is infected. This drug needs to be injected twice daily 
and its use is reserved for treatment of heavily 
drug-experienced patients since it can help overcome 
existing drug resistance.111,112 Development of new 
antiretrovirals focuses on molecules that target entry, 
reverse transcription, integration, or maturation. 
Compounds that have been designed to inhibit resistant 
viruses are urgently needed since many patients treated 
during the past decades harbour viral strains with reduced 
susceptibilities to many if not all available drugs (table 3). 
The goal of antiretroviral treatment is to decrease the 
morbidity and mortality that is generally associated with 
HIV-1 infection. A combination of three or more active 
drugs is needed to achieve this aim in most patients. 
Eff ective treatment returns to near normal the turnover 
rates of both CD4+ and CD8+ T-cell populations.72 Potent 
but well tolerated drugs with long half-lives and simplifi ed 
regimens improve the options for fi rst-line and second-line 
chemotherapeutic interventions. 
Combination antiretroviral treatment
High rate of viral replication, low fi delity of reverse 
transcription, and the ability to recombine are the viral 
characteristics that lead to the diversity of HIV-1 species 
(quasi-species) in chronically infected individuals. This 
high genetic variability provided the rationale for highly 
active antiretroviral treatments (HAART). By combination 
of several potent antiretroviral agents, viral replication is 
suppressed to such low levels that emergence of drug 
resistant HIV-1 variants was, if not prevented, at least 
delayed. By doing so, CD4+ T-lymphocyte numbers 
increase, leading to a degree of immune reconstitution 
that is suffi  cient to reverse clinically apparent 
immunodefi ciency. Widespread introduction of HAART 
in industrialised countries resulted in a striking decrease 
in morbidity and mortality, putting forward the hope that 
HIV-1 infection can be transformed into a treatable chronic 
disease.113–115 
A set of criteria composed of plasma viraemia 
concentration, absolute or relative CD4+ cell counts, and 
clinical manifestations, is used to recommend initiation 
of HAART. The benefi ts of treatment clearly outweigh the 
potential side-eff ects in patients with clinical signs of 
immunodefi ciency (eg, AIDS defi ning illnesses) or with 
CD4+ numbers less than 200 per µL (recommendation of 
US Department of Health and Human Services, October, 
2005). However, the best time point to begin treatment 
remains controversial in asymptomatic patients with 
modest depletion of CD4+ T cells (eg, more than 
350 per µL) and modest levels of viraemia (eg, less than 
100 000 copies per mL).116 Studies with clinical endpoints 
supporting the validity of early versus late interventions in 
asymptomatic patients are diffi  cult to do and insuffi  cient 
clinical data are currently available. Early depletion of gut 
CD4+ T lymphocytes,117 increasing viral diversity, and the 
Drug Mechanism Activity against PI and RT resistant strains
Maraviroc MVC CCR5 inhibitor Yes, but not X4 variants
Vicriviroc SCH D Yes, but not X4 variants
Etravirine TMC-125 Non-nucleoside reverse 
transcriptase inhibitor
Yes, also NNRTI-resistant strains
TMC-278 Yes, also NNRTI-resistant strains
n/a MK-0518 Integrase strand transfer inhibitor Yes
n/a GS-9137 Yes
Table 3: Antiretrovirals currently in phase II/III of clinical development
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poor regenerative abilities of key populations of the 
immune system provide arguments for beginning 
treatment as early as possible. The wide application of this 
principle is restricted by long-term drug toxicities that lead 
to reduction of quality of life, and by treatment costs. 
Toxicities (eg, renal, hepato, mitochondrial), metabolic 
changes (eg, lipodystrophy, diabetes mellitus), and 
immune reconstitution disease are some of the long-term 
problems that complicate decade-long HAART.118–121
One strategy addressing life-long daily compliance to 
HAART has been structured treatment interruptions. The 
rationale for this approach was based on the premise that 
the body’s own immune system could keep the virus in 
check if exposed to a very modest level of viral replication. 
If successful, this strategy could limit drug toxicity and 
reduce treatment costs.122 Although preliminary fi ndings 
for this strategy were mixed in terms of benefi ts,123–125 the 
recent early closure of the SMART trial was based on 
increased morbidity and mortality in the treatment 
interruption arm.126 Thus, in the absence of clinical 
benefi ts, most investigators strongly discourage treatment 
interruptions except as needed to address treatment 
intolerance. 
HAART in resource-constrained settings
The transformation of AIDS into a chronic disease in 
industrialised countries has yet to be realised in 
resource-constrained settings. Access to HAART is an 
absolute humanitarian necessity to avert mortality in 
people who are central to the future survival of their 
countries.127 Despite restricted health infrastructures and 
diverse co-morbidities in these regions, remarkable 
therapeutic success rates have been shown, with adherence 
rates at least comparable with those reported in 
industrialised countries.128–131 WHO and UNAIDS 
treatment guidelines focusing on resource-limited 
settings suggest use of standard fi rst-line regimen 
followed by a set of more expensive second-line options132 
and proposes the use of standardised decision-making 
steps (eg, when to start, to substitute for side-eff ects, to 
switch for virological failure).132,133 In many countries, 
treatment options are limited not only by the costs of 
HAART but also by restrictive licensing policies, and 
current estimates suggest that 80% of people infected 
with HIV-1 with a clinical need for treatment do not yet 
have access to antiretroviral drugs.1 Thus, eff orts and 
strategies to further scale up treatment access are 
crucial,134–137 since antiretroviral treatment is also an 
eff ective intervention for prevention.138
Drug resistance
Emergence of drug resistance is the most common 
reason for treatment failure. Insuffi  cient compliance, 
drug side-eff ects, or drug-drug interactions can lead to 
suboptimum drug concentrations, resulting in viral 
rebound. Viral resistance has been described to every 
antiretroviral drug and therefore poses a serious clinical 
as well as public-health problem.139 HIV-1 subtypes diff er 
in the sequence of mutations leading to drug resistance, 
and some naturally occurring polymorphisms might 
actually modulate resistance.140,141 Drug-resistant HIV-1 is 
transmissible and can be detected in up to 20% of newly 
infected individuals in countries with broad access to 
antiretrovirals.34 The prevalence of drug resistance in 
the untreated population remains low in regions with 
poor access to treatment.142 
Short-term antiretroviral-based interventions are 
eff ective in prevention of mother-to-child transmission. 
However, these interventions could result in drug 
resistant viral variants in the mother, baby, or both.143 
Around half the women who received one dose of 
nevirapine to prevent mother-to-child transmission 
harbour viruses resistant to non-nucleoside reverse 
transcriptase inhibitors (NNRTI).144,145 These resistant 
viruses replicate effi  ciently and can be transmitted by 
breast milk,146 and minor resistant populations present 
long after the intervention can possibly decrease the 
eff ectiveness of subsequent NNRTI-based treatment 
regimens.147 The combination of short-course zidovudine, 
lamivudine, and nevirapine prevents peripartum 
transmission while reducing the risk of nevirapine 
resistant viruses.148
Viral reservoirs
Viral reservoirs consist of anatomical sanctuaries and a 
small pool of infected long-lived memory T lymphocytes. 
HIV-1 latency in long-lived cell populations (eg, memory 
T lymphocytes, macrophages) poses an obstacle to 
eradication because current antiviral combination 
treatments fail to eliminate integrated proviruses from 
resting cells. Diff erent strategies, including im-
mune-modulatory molecules (interleukin 2, anti-CD3 
mAb, interleukin 7), have been used to reactivate resting 
cells in the setting of HAART. Histone deacetylase-1 
inhibitors, like valproic acid, release an inherent 
transcriptional block and by doing so facilitate viral long 
terminal repeat-driven expression.149 Augmenting standard 
antiretroviral treatment with enfuviridine and valproic 
acid reduced the number of latently infected CD4+ T cells 
(29–84%), but to establish the relative contribution of each 
drug with respect to the fi nal outcome is diffi  cult.150
Prevention 
Mother-to-child transmission
Prevention of mother-to-child transmission has seen 
advances in both industrialised and resource-constrained 
settings.151–153 Intrapartum transmission has been 
reduced by increasing access to interventions such as 
one dose of nevirapine to mother and newborn baby.154 
Concerns about drug-resistant viral strains have led to 
several trials with combination treatments to reduce 
transmission during the intrapartum period.148,152,155 In 
some settings, elective delivery by caesarean section can 
further reduce HIV-1 transmission during the 
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intrapartum period, but the benefi ts of the intervention 
could be countered by post-partum sepsis and increasing 
maternal mortality.156
Because HIV-1 can be transmitted by breastfeeding, 
replacement feeding is recommended in many settings. 
Poor access to clean running water precludes, however, 
the use of formula feeding under these circumstances,157 
and exclusive breastfeeding with abrupt weaning is one 
option for reducing transmission.158 A potential novel 
intervention still being tested is the daily use of 
antiretrovirals during breastfeeding. More attention is 
starting to focus on the pregnant mother, especially 
initiation of antiretroviral therapy in mothers with low 
CD4+ counts during pregnancy and thereafter.159,160 Only 
limited data are available regarding the health of 
uninfected children born to HIV-1-positive mothers.161 
In a European cohort of exposed-uninfected children, 
no serious clinical manifestations were apparent, at 
least in the short term to medium term (median 
follow-up 2 years).162
Sexual transmission 
Reduction of heterosexual transmission is crucial for 
control of the epidemic in many parts of the world.1,163 
Prevention is achieved through reduction in the number 
of discordant sexual acts or reduction of the probability 
of HIV-1 transmission in discordant sexual acts. The 
fi rst can be achieved through abstinence and sex 
between concordantly seronegative individuals. 
Abstinence and lifelong monogamous relationships 
might not be adequate solutions for many people and 
therefore several interventions aimed at lowering the 
risk of transmission per discordant sexual act are in the 
process of clinical testing. Male and female condoms 
provide a proven and aff ordable prevention option.164,165 
In combination, these options are also more commonly 
referred to as the ABC (abstinence, be faithful, condom 
use) approach. 
Other biomedical prevention interventions include 
male circumcision, antiretrovirals for prevention (eg, 
pre-exposure or post-exposure), chemoprophylactic 
treatment of herpes simplex virus-2 (HSV-2), 
microbicides, and vaccines. Results from one of three 
independent phase III male circumcision trials 
underway in South Africa, Kenya, and Uganda has 
helped to allay some of the ambivalence around the 
protective eff ect of male circumcision.8,166 The fi ndings 
from the South African trial show a 60% protective 
eff ect of male circumcision.167 The possible mechanism 
relates to the fact that the foreskin has apocrine glands 
that secrete lysozymes but also Langerhans cells 
expressing CD4 and other receptors.168,169 These 
skin-specifi c dendritic cells can uptake virus and are 
believed to play a part in transport of the virus to 
susceptible T cells. Immunofl uorescence studies of 
foreskin mucosa suggest that these tissues might be 
more susceptible to HIV-1 infection than cervical 
mucosa.170 Findings from this proof-of-concept trial need 
to be compared with evidence from the two trials still 
underway in Kenya and Uganda, and to acceptability 
data, behaviour change after circumcision, surgical 
complication rates, and logistics of undertaking the 
procedures before policy formulation and wide-scale 
access as a prevention strategy.171–173
Since high plasma viraemia increases the risk of 
transmission by as much as an order of magnitude,21 
does reducing viral load in the infected partner through, 
for example, antiretroviral treatment reduce the risk of 
HIV-1 transmission in the uninfected sexual partner? A 
trial to explore this question is currently being run 
jointly by the HIV Prevention Trials Network (www.
hptn.org) and the Adult Clinical Trials Group. 
Mathematical projections estimate up to 80% HIV-1 
reduction,174,175 but scarce observational data currently 
exist.176 Post-exposure prophylaxis is recommended after 
occupational (eg, needle stick)177 and non-occupational 
(eg, rape, sexual abuse)178 exposure, although data for 
effi  cacy and optimum drug combinations are few.179 
Some clinical trials assessing the benefi ts of once daily 
pre-exposure chemoprophylaxis with antiretroviral 
compounds with long biological half-life (eg, tenofovir) 
have been put on hold or stopped.175,180 Neither the overall 
idea of pre-exposure prophylaxis nor the drug itself, 
which is well tolerated, was at the root of the protests. 
Concerns were centred on clinical trials in resource-poor 
settings and the perceived scarcity of adequate 
interventions protecting these vulnerable populations. 
HSV-2 might increase both the risk of transmitting 
and acquiring HIV-1.181,182 Antivirals (eg, aciclovir, 
valaciclovir) are eff ective in reducing viral shedding183–185 
and HSV-2 transmission in discordant heterosexual 
couples.182 The future of HSV-2 prevention might reside 
in the vaccine that is currently under development.186 
Whether prophylactic use of aciclovir in populations 
with high HSV-2 prevalence and incidence rates results 
in reduced HIV-1 incidence rates remains unresolved 
but several trials addressing this issue are underway, 
including HPTN039. 
Gender disparities lie at the centre of women’s 
vulnerability. Prevention options need to be provided that 
can be used by women independently of their male sexual 
partner’s knowledge or consent.187 Notwithstanding that 
redressing these disparities is a long-term challenge, 
several preventive interventions can be implemented in 
the interim on the basis of our incomplete understanding 
at a biological level of HIV-1 risk for women. For example, 
there seems to be a correlation between levels of sexual 
hormones (eg, progesterone) and transmission risk.188 
Observational studies also highlight the relation between 
abnormal vaginal fl ora and increased risk of HIV-1 
infection.189,190 The high prevalence of vaginal infections 
such as bacterial vaginosis (30–50%), vulvovaginal 
candidosis (10–13%), and trichomonas vaginalis (7–23%) 
in African women is associated with a substantial risk of 
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HIV-1 acquisition.189 In addition to increasing access to 
female condoms and treatment of other sexually 
transmitted infections, trials are underway to assess the 
use of other barrier methods such as cervical caps, 
invisible condoms, diaphragms, and diaphragms 
combined with micro bicides.190 The control of vaginal 
infections is a potentially important method for decreasing 
HIV-1 acquisition that has yet to be tested. Periodic 
presumptive treatment for vaginal infections is being 
explored as an HIV-1 prevention strategy.191 
Microbicides
Microbicides are an additional important biomedical 
intervention technology that is covert and under women’s 
control.192 These topical products potentially could be 
used to prevent rectal and vaginal transmission of HIV-1, 
but proof of concept has been elusive. Although the three 
phase III trial results of the fi rst microbicidal product 
(nonoxynol-9) done in the mid-1980s and 1990s did not 
show protective eff ects,193,194 they have informed the 
medical knowledge in terms of product selection, clinical 
testing, and safety assessments. The past 5 years have 
seen major advances in investment and product 
development.66,195,197 Early clinical testing of multiple 
products including the launch of advanced clinical trials 
for fi ve diff erent products is continuing (table 4). The 
development of antiretroviral gels increased the specifi city 
of these third generation microbicides in relation to 
surfactants, vaginal enhancers, or entry inhibitors that 
have dominated the product pipeline so far (fi gure 5). 
The fi rst antiretroviral gel to undergo early testing is 
tenofovir gel, and the fi ndings in terms of safety profi le, 
tolerance, low systemic absorption, and slight adverse 
events are promising.192 As with vaccines, a major obstacle 
is the absence of a surrogate marker of protection. 
Additional challenges are adherence to product use and 
the high rates of pregnancy in trial participants.
Vaccines
A safe, protective, and inexpensive vaccine would be the 
most effi  cient and possibly the only way to curb the HIV 
pandemic.198 Despite intensive research, development of 
such a candidate vaccine remains elusive. Safety concerns 
prohibit the use of live-attenuated virus as immunogen.199 
Many diff erent approaches with recombinant technologies 
have been pursued over the past two decades. Initially, 
eff orts were focused on generating neutralising antibodies 
with recombinant monomeric envelope gp120 (AIDSVAX) 
as immunogen.200,201 This vaccine did not induce 
neutralising antibodies and, not unexpectedly, the phase 
III trials failed to show protection.202,203 Antibody mediated 
HIV-1 neutralisation is complicated by the high genetic 
diversity of the variable Env regions, epitopes masked by a 
carbohydrate shield (glycosylation), and conformational or 
energetic constraints.204 Since CD8 T-cell responses control 
to some extent viral replication in vivo, recent vaccine 
development has focused on eliciting cellular immune 
responses. Overcoming pre-existing immunity against 
replication incompetent immunogenic vectors (eg, 
recombinant adenovirus type 5) is one of the challenges.205 
Safety and immunogenicity studies using replication 
defective vaccine vectors are continuing after preliminary 
studies in non-human primates showed some protection.204 
The immune system generally fails to spontaneously clear 
HIV-1 and the true correlates of protection continue to be 
ill defi ned.198,206 However, the general belief is that 
approaches aimed at eliciting both humoral and cell 
mediated immunity are most promising to prevent or at 
least control retroviral infection.198 
Conclusions
An important gateway to both prevention and care is 
knowledge of HIV-1 status.207 Fear of knowledge of status, 
including stigma and discrimination, has discouraged 
many from seeking voluntary counselling and testing 
services.208 As access to antiretroviral interventions 
(prevention of mother-to-child transmission, antiretroviral 
treatment) increases, the opportunities for HIV-1 testing 
will grow and create opportunities for a prevention-care 
continuum, with the voluntary counselling and testing 
Phase Mode of action Eff ective against
Carraguard III Seaweed polymer, entry inhibitor HIV-1/HIV-2, human papilloma virus, herpes simplex virus
Cellulose sulphate III Entry inhibitor Broad range of sexually transmitted diseases; also active as contraceptive
PRO2000 III Entry inhibitor HIV-1/HIV-2, human papillomavirus, chlamydia
Savvy (C31G) III Surfactant Broad range of sexually transmitted diseases; also active as contraceptive
Tenofovir gel IIb Nucleotide reverse transcriptase inhibitor HIV-1/HIV-2
Buff er gel+PRO2000 IIb/III Natural vaginal defence/entry inhibitor HIV-1/HIV-2, chlamydia, gonorrhoea, human papillomavirus, bacterial vaginosis
Tenofovir gel+oral II Nucleotide reverse transcriptase inhibitor HIV-1/HIV-2
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services as a point of entry. These changes will result in a 
shift in prevention eff orts from a focus on individuals not 
infected with HIV-1 to a more eff ective continuum of 
prevention that includes uninfected, recently infected, 
infected, and asymptomatic people, as well as those with 
advancing HIV disease and on antiretroviral therapy. 
HIV/AIDS is an exceptional epidemic that demands an 
exceptional response. Much progress has been made in a 
short space of time, despite many scientifi c and 
programmatic challenges (fi gure 6). In the absence of a 
protective vaccine or a cure, prevention and access to 
antiretroviral treatments are the best options to slow 
down the HIV-1 pandemic. Broad implementation of 
these principles needs improved infrastructures in 
resource-constrained regions, which have been and 
will continue to be most aff ected. The fact that 
HIV-1 is predominantly sexually transmitted and 
disproportionately aff ects populations that are already 
socially or economically marginalised, or both, poses many 
ethical, social, economic, and political challenges. 
In view of the immediacy of the problem, and the fact 
that both research and programmes are mainly funded by 
the public sector, there is a greater demand from civil 
society for co-ownership of research and accountability for 
use of public funds. On the one hand, this co-ownership 
defi nes a changing role and responsibility of science in 
society, and on the other hand, shows a necessary synergy 
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Figure 6: Selected observations, scientifi c developments, and treatment options pertinent to HIV-1/AIDS
 Estimates place the cross species transmission events leading to the worldwide spread of HIV-1 to the early decades of the 20th century. Numbers circled by a 
hexagon identify the specifi c year of an event. PEPFAR=President’s Emergency Plan for AIDS Relief. 
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invaluable for antiretroviral drug development, treatment 
access in resource-constrained settings, and the scale-up of 
interventions to reduce mother-to-child transmission. 
The increasing number of infected women and the 
disproportionate burden of infection in resource-
constrained settings creates a scientifi c imperative to 
ensure research is done for people and in settings who 
stand to benefi t most. The most aff ected countries face 
many other economic, political, and development 
challenges, which have raised issues in undertaking 
multicentre and multicountry research. Research 
addressing women-specifi c topics (such as eff ect of sexual 
hormones on transmission and disease progression, viral 
diversity, and antiretroviral potency) and women-specifi c 
prevention interventions including microbicides is crucial. 
We are probably at one of the most hopeful and optimistic 
points in our response to the pandemic. There is defi nitely 
more attention being directed to HIV-1, more resources 
(panel), more civil society mobilisation, more governments 
speaking up, more possibilities for treatment, and more 
evidence about what prevention and treatment strategies 
will work than in previous years. The unrelenting growth 
of the pandemic tells us that current strategies are not 
enough. Clearly, we need to do some things diff erently, 
while also increasing the scale and magnitude of current 
strategies in keeping with the pandemic. 
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